E
Power Law company profile
Editas Medicine
Biotech & Life Sciences · Cambridge, United States · Founded 2013 · IPO 2016 Unicorn
Valuation
$148M
Market cap · Apr/2026
Revenue
$41M
Latest reported FY
Global footprint
Where Editas Medicine has talent and traffic
AI talent share
1.1%
of workforce is AI talent
(2 of 183 staff)
(2 of 183 staff)
Core AI10.55%
Other AI10.55%
Non-AI workforce18198.91%
Web traffic by country
18K
monthly visits
across markets
across markets
🇺🇸 United States80%
🇩🇪 Germany7.2%
🇨🇦 Canada6.1%
🇮🇳 India4.4%
🇦🇺 Australia1.1%
Patent intelligence
$69M patent portfolio · 74 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$69M
46.6% of market cap · 29.5× smaller than top peer Ablynx ($2B)
74 active patent families
Where Editas Medicine innovates
Molecular biologyBioinformaticsCellCRISPRCell biology
Above peer median on Legal, Market
Quality vs same-sector peers
Editas Medicine on the five Patsnap quality dimensions
Editas Medicine in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Editas Medicine concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Editas Medicine and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Editas Medicine on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.